You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,207,280

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,207,280 protect, and when does it expire?

Patent 11,207,280 protects ADRENALIN and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 11,207,280

Patent landscape, scope, and claims:

Title:	Epinephrine compositions and containers
Abstract:	The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
Inventor(s):	Akasapu Prem Sagar, Soppimath Kumaresh, Puri Reema Ajitkumar, Ilitchev Iouri V., Patel Milan, Tendulkar Pooja H.
Assignee:	Nevakar Injectables Inc.
Application Number:	US16821785
Patent Claim Types: see list of patent claims
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,207,280

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-001	Apr 21, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-002	Apr 21, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-003	Apr 21, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-004	Apr 21, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-005	Apr 21, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,207,280

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3093725	⤷ Subscribe
World Intellectual Property Organization (WIPO)	2019183416	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.